A recent study found that, due to higher incidence of prostate cancer in black man, PSA testing may need to be started earlier in this population, and be done more frequently.
A “one size fits all” approach to prostate-specific antigen (PSA) screening for prostate cancer may not be the right way to go about it, according to a new study published online in CANCER, which suggests that policies may need to be tailored to high-risk black men.
The American Cancer Society states that among black men in the United States, the incidence of prostate cancer is 60 percent higher than that of white men, and they are also more than twice as likely to die from the disease.
A team of researchers from the Fred Hutchinson Cancer Research Center in Seattle, the University of Michigan in Ann Arbor and Erasmus University in the Netherlands examined the reason why this disparity occurs by using three models of prostate cancer incidence and PSA screening in the U.S. to estimate disease onset and progression. The data was taken from the Surveillance, Epidemiology, and End Results program of the National Cancer Institute from 1975 to 2000.
The researchers noted that by age 85 an estimated 30 to 43 percent of black men develop preclinical — asymptomatic — prostate cancer, making them 28 to 56 percent more likely to develop preclinical disease than men of any other race.
“We found that the interval from getting preclinical cancer to being diagnosed is long — 10 years or more on average — and is similar in black and white men,” Ruth Etzioni, Ph.D., Fred Hutchinson Cancer Research Center, said in a statement. “But during that interval, cancers in black men tend to progress faster. What this means is that in developing screening policies for black men, it will be important to consider beginning screening them at an earlier age and potentially screening them more frequently than would be recommended by general population guidelines.”
The study found that among men with preclinical disease, black men have a similar risk of being diagnosed with prostate cancer (35 percent to 49 percent) compared with the general population (32 percent to 44 percent) in the absence of screening. Their risk of progression to advanced disease by the time they’re diagnosed is 44 percent to 75 percent higher than in the general population, with a 12 to 13 percent risk in black men versus a 7 to 9 percent risk in the general population.
Etzioni and her colleagues suggest that black men should have their baseline PSA tested at least three and up to nine years earlier than men in the general population.
In addition, Etzioni stressed that additional research is needed to determine the best policies for prostate cancer screening in black men. The authors also noted that this may be a time to start focusing on more personalized approaches to screening in high-risk black men.
Last month, the United State Preventative Services Task Force drafted new guidelines for PSA screening, now recommending that men aged 55 to 69, talk with their physician about screening, and then decide on the best course of action together.